AbbVie (ABBV)

It's no reason to stay up at night.

Healthcare stocks have far outperformed the broader market over the past month.

Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends.

These stocks pay income that investors can count on over the long run.

A $10,000 investment in this diversified fund at its 2011 inception would be worth $51,000 today.

These top dividend payers could enrich a long-term investor's portfolio.

A key trading signal flashed for AbbVie shares at a price of $228.47, after which ABBV rose as much as 2.4% to an intraday high of $233.90.

The Dow Jones Industrial Average (DJIA) has surged to unprecedented levels, marking new all-time highs this week, even as the nation holds its breath for a pivotal vote in the U.S. House of Representatives. On Tuesday, November 11, 2025, the Dow closed at a record 47,927.96, continuing

New York, NY – November 12, 2025 – The U.S. stock market presented a landscape of diverging fortunes today, as the Dow Jones Industrial Average surged to new record highs, fueled by mounting optimism for an end to a protracted government shutdown, while the tech-heavy Nasdaq Composite experienced a notable decline.

Stat News reported on Wednesday, citing internal emails, that the move comes amid AbbVie’s shift away from small-molecule drugs, including pills.

These three healthcare stocks are outperforming most of the sector.

All 5 stocks have upside potential heading into 2026.

The economic outlook for the U.S. Midwest has taken a concerning turn as the Chicago Federal Reserve's 7th District hiring expectations index reportedly plummeted to -40 in October 2025. This alarming figure represents the lowest reading for hiring expectations since the tumultuous year of 2020 and, excluding the pandemic

Healthcare stocks in the S&P 500 offer an average dividend yield of 1.8%.

These stocks are priced low, have encouraging growth prospects, and also pay dividends.

AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales growth from Skyrizi and Rinvoq, as well as double-digit expansion in neuroscience products, as key contributors to the performance. However, despite surpassing Wall Street revenue and profit estimates, the market reacted negatively, reflecting heightened concern over a sharp drop in operating margin and the persistence of headwinds in the aesthetics segment. CEO Rob Michael acknowledged challenging economic conditions affecting discretionary spending and emphasized the company’s execution in core therapeutic areas.

These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in turn, significantly bolstered the US Dollar, pushing it to multi-month highs against a basket of major currencies. The immediate implication for

Linzess is the first treatment approved for the disease in pediatric patients, the FDA said.

Healthcare has been an extraordinarily resilient industry to put cash to work in through the years.

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.